ORCA Therapeutics licenses oncolytic adenovirus technology from VCN Biosciences
02-Oct-2009 -
ORCA Therapeutics BV announced that it has obtained an exclusive license from VCN Biosciences SL of Gelida (Barcelona), Spain, to their T1 oncolytic adenovirus technology for the treatment of cancer. This license allows ORCA Therapeutics to develop and commercialize new, next generation oncolytic ...
adenovirus
oncology
Spain
+1